Viemed Healthcare (VMD) grows to $270M revenue and guides up for 2026

Rhea-AI Filing Summary

Viemed Healthcare used a new investor presentation to highlight strong 2025 performance and 2026 guidance. For 2025, the company reported $270M in net revenue, $61M Adjusted EBITDA, $28M free cash flow, nine straight years of positive net income, and effectively $0M net debt.

The business is increasingly diversified, with sleep representing 21% of Q4 2025 net revenue and showing 62% year-over-year growth in PAP therapy patients and 49% growth in sleep resupply patients. Management is guiding 2026 net revenue to $310M–$320M and Adjusted EBITDA to $65M–$69M, with net capex of 10%–11.5% of net revenue.

The company emphasizes a capital-light, home-based care model, expanding from complex ventilation into sleep, oxygen, airway clearance, women’s health and staffing. With more than 172,000 patients across all 50 states, $46M of credit facility availability, and a newly authorized share repurchase program covering up to 5% of shares outstanding, Viemed presents itself as a growth platform supported by regulatory stability and a strong balance sheet.

Insights

Healthcare services equity analyst

Viemed posts strong 2025 growth, issues solid 2026 guidance with no net debt.

Viemed Healthcare reports 2025 net revenue of $270M and Adjusted EBITDA of $61M, reflecting a diversified, home-based respiratory and sleep platform. Free cash flow of $28M and nine consecutive years of positive net income signal a financially mature business model.

Growth is increasingly driven by sleep therapy, which reached 21% of Q4 2025 net revenue, supported by 62% year-over-year growth in PAP therapy patients and 49% growth in sleep resupply patients. Ventilator patients still expanded, but at a slower 4% year-over-year pace, indicating mix shift toward newer lines.

For 2026, management guides net revenue to $310M–$320M and Adjusted EBITDA to $65M–$69M, while keeping net capex at 10%–11.5% of net revenue. With $0M net debt, $46M of credit facility capacity, and authorization to repurchase up to 5% of shares outstanding, capital allocation balances organic investment, M&A, and shareholder returns.

0001729149false00017291492026-03-162026-03-16

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2026

Viemed Healthcare, Inc.

(Exact name of registrant as specified in its charter)

British Columbia, Canada

001-38973

N/A

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

625 E. Kaliste Saloom Rd. Lafayette, Louisiana						70508
(Address of principal executive offices)						(Zip Code)

(337) 504-3802

(Registrant’s telephone number, including area code) 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common shares, no par value			VMD			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.     Regulation FD Disclosure

Viemed Healthcare, Inc. (the “Company”) expects to use the presentation attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Investor Deck Presentation”) and incorporated herein by reference, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. The Investor Deck Presentation is also available on the Company’s website, https://www.viemed.com/investors.

The information contained in the Investor Deck Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as required by law although it may do so from time to time as its management believes is warranted.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01.    Financial Statements and Exhibits

(d) Exhibits

Exhibit Number						Description
99.1						Viemed Investor Deck Presentation March 2026
104						Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 16, 2026

VIEMED HEALTHCARE, INC.
By:						/s/ Trae Fitzgerald
						Trae Fitzgerald
						Chief Financial Officer

A Rapidly Growing National Leader In Home-Based Clinical Care. Investor Presentation: NASDAQ: VMD March 2026 VieMed Healthcare Inc. • Investor Presentation 1

Disclaimers VieMed Healthcare Inc. • Investor Presentation Disclaimers and Other Important Information This presentation (the “Presentation”) about VieMed Healthcare, Inc. (“VieMed” or the “Company”) is dated March 2026. It presents information in a summary form and does not purport to be complete. The data contained herein is derived from various internal and external sources. This Presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. No representation or warranty, express or implied, is made or given by or on behalf of VieMed or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. VieMed does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice. This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of VieMed in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Recipients of this Presentation who are considering acquiring securities of VieMed are referred to the entire body of publicly disclosed information regarding VieMed. The information is subject to material updating, revision and further amendment, and is qualified entirely by reference to VieMed’s publicly disclosed information. Forward Looking Statements Certain statements contained in this Presentation may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward- looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue and Adjusted EBITDA guidance for 2026, the Company’s growth strategy, including its plans for geographic expansion, diversification of payor and product mix, technology initiatives, and potential future acquisitions or partnerships, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect VieMed's current views and intentions with respect to future events, and current information available to VieMed, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, the use of artificial intelligence technologies, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in VieMed’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including VieMed’s most recent Annual Report on Form 10-K and quarterly report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect VieMed in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, VieMed does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this Presentation are made as of the date of this Presentation and VieMed undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law. This Presentation contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. Market and Industry Data Industry and market data used in this Presentation is unaudited and have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. VieMed has not independently verified the data obtained from these sources and cannot assure you of the data’s accuracy or completeness. This data is subject to change and cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market or industry data. You are cautioned not to give undue weight to such industry and market data. Non-GAAP and Other Financial Information This Presentation includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including the measures Adjusted EBITDA and free cash flow. A reconciliation of these non-GAAP financial measures to the nearest GAAP measures can be found in the Appendix to this Presentation. 2

An innovative, national in-home healthcare leader built on clinical excellence... High-touch and high-tech services care model drives cost reduction, increases patient satisfaction and reduces rehospitalizations. VieMed Healthcare Inc. • Investor Presentation 3 Founded in 2006 • Public since 2017 • Headquartered in Lafayette, Louisiana Built a Platform Around Complex Respiratory Services Extensive Nationwide Reach Innovative At-Home Healthcare Robust Growth and Financial Performance 26% compounded annual revenue growth rate since public listing, $28M FCF in 2025, and no net debt. Serving over 172,000 patients with a capex-light business model in all 50 states. Home-based care platform built on the reputation of clinical excellence in ventilation. Now leveraging our core platform to include sleep, oxygen, airway clearance and maternal health.

…led by an experienced management team… VieMed Healthcare Inc. • Investor Presentation 4 Casey Hoyt CEO and original founder 20+ years with VieMed Michael Moore, RRT President and original founder 20+ years with VieMed Todd Zehnder Chief Operating Officer 10+ years with VieMed Randy Dobbs Board of Directors, Chairman 10+ years with VieMed William Frazier, MD Chief Medical Officer 10+ years with VieMed Trae Fitzgerald Chief Financial Officer 10+ years with VieMed Combined management team brings 80+ years of public company experience across GE, Philips, NYSE-listed companies, and Big 4 accounting ~ $287M Market Cap >20% Insider Beneficial Ownership (1) Market cap as of 12-31-2025 1

...with multiple catalysts driving our growth. 5 VieMed Healthcare Inc. • Investor Presentation Massively underserved market with a purpose-built clinical model to close the gap Complex respiratory care and obstructive sleep apnea remain meaningfully underdiagnosed and undertreated. VieMed's high-touch, technology-enabled approach is designed to reach patients where traditional providers cannot. A vital link between patients, providers, and payors with measurable outcomes Our clinical care model improves patient compliance, reduces hospitalizations, and drives payer value. Designed to create lasting relationships and a defensible competitive position. Proven growth platform with a broadening service mix Organic and inorganic expansion has diversified VieMed well beyond our ventilation roots. Our entry into maternal health is the most recent example of leveraging shared infrastructure for capital-light growth into adjacent markets. Regulatory tailwinds favor our model The shift toward home-based care, efficiency, compliance, and transparency plays directly to VieMed's strengths. We are uniquely positioned to succeed in this environment.

Complex respiratory care is the foundation of our business... VieMed Healthcare Inc. • Investor Presentation Vent Patients on Service 6,500 7,500 8,500 9,500 10,500 11,500 12,500 4Q20 2Q21 4Q21 2Q22 4Q22 2Q23 4Q23 2Q24 4Q24 2Q25 4Q25 1 (1) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter. 6 Attractive Unit Economics Monthly Reimbursement ~$1,050 Avg. Length of Stay ~17 months Rental Structure Uncapped Service Model 24/7 RT included Coverage Medicare + most plans

...serving a population that is massively underserved... (1) As of 2024 (source: HME Databank) VieMed Healthcare Inc. • Investor Presentation 25 Million (estimated) people in the U.S. have COPD Approximately 70,000 annual Medicare beneficiaries on NIV service Estimate of 6% market penetration 2,500,000 or 10% have stage 4 COPD 1,250,000 or 50% of those with stage 4 COPD develop chronic respiratory failure becoming candidates for our therapy VIEMED IS THIRD LARGEST PROVIDER MARKET SHARE HELD BY TOP 10 PROVIDERS 14% 62% 7 1 1 1

... through a tech-enabled, clinical model that sets us apart... Proprietary clinical platform, connecting best-in-class clinical service with best-in-class devices Increase patient and caregiver engagement Increase efficiency of clinicians through improved remote workflow and proactive patient engagement solutions Capture value-based data elements, analysis and insights from patient’s home to improve patient outcomes and generate cost savings 24/7 Respiratory Therapist included in service VieMed Healthcare Inc. • Investor Presentation 8

...and backed by real-world outcomes. VieMed Healthcare Inc. • Investor Presentation Non-invasive ventilation at home reduces mortality in COPD with CRF September 15, 2021 December 29, 2020June 29, 2022 Sample size: 500,000 patients Sample size: 36,000 patients Sample size: 45,000 patients 43% Relative mortality reduction if utilized within 0-7 days 11.6% Cost reduction if utilized within 0-7 days 7.2% Cost reduction if utilized within 0-15 days $5,484 Cost reduction if utilized within 0-7 days Early initiation of non-invasive ventilation at home reduces mortality, hospitalizations, and overall health costs Non-invasive ventilation at home reduces mortality in COPD with CRF 31% Relative reduction in hospital readmissions 38% Immediate reduction in risk of death with NIV 12% Relative reduction in mortality after 12 months 16% Relative reduction in ER visits Non-invasive ventilation at home improves survival and decreases healthcare utilization 39% Relative reduction in all-cause mortality over 7-year period 9% Relative decline in the risk of hospitalizations 22% Relative reduction in the risk of an ER visit 9

Our unique operating model has opened doors to expand our patient base… VieMed Healthcare Inc. • Investor Presentation 10 L E A N O P E R A T I N G M O D E L ✓ No retail storefronts Minimal brick-and-mortar limited to small distribution hubs ✓ Mobile workforce Sales reps and RTs operate from GPS-monitored vehicles, delivering care directly to patients’ homes ✓ Data-driven location selection Target areas with high COPD rates, hospitals struggling with length of stay, and rural markets near existing coverage ✓ Lean market entry New geographies require clinical talent and payer contracts; dual role RTs to start P R O D U C T O F F E R I N G S What fits our current national model Clinician-delivered, remotely monitored services: • Ventilation therapy • PAP therapy & supplies • Breast pumps & maternal support • Stationary and Portable O₂ concentrators • Airway clearance devices Outside our current national model Heavy-logistics DME requiring storefronts and warehousing: • Wheelchairs & mobility • Hospital beds • Bulky oxygen tanks Our unique model drives lower overhead, faster geographic expansion, and higher margins than traditional DME competitors. ✓ Technology focus Focus on products with technology enablement vs. “bent metal” ✓

Ventilation 48% Airway Clearance 7% Oxygen 8% Sleep 21% Maternal 6% Staffing 8% Other 2% Ventilation 87% Airway Clearance 5% Oxygen 1% Sleep 6% Other 1% Medicare 35% Medicaid /MCO 8% Medicare Advantage 21% Commercial 24% Other 12% Medicare 50% Medicaid/ MCO 7% Medicare Advantage 21% Commercial 16% Other 6% … and six years later, the numbers tell the story. SERVICE MIX PAYOR MIX VieMed Healthcare Inc. • Investor Presentation Diverse and Reliable Revenue Streams Q4 2025FY 2019 FY 2019 Q4 2025 11 Ventilation revenue has doubled since 2019, with a broadening platform accelerating alongside it.

- 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 PAP Therapy Patients Sleep Resupply Patients VieMed Healthcare Inc. • Investor Presentation (1) PAP Therapy patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter. (2) Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter. (3) American Lung Association 1 2 12 Sleep is the clearest example of what that looks like… 62% YoY PAP Patient Growth 49% YoY Resupply Growth 21% of 4Q25 Net Revenue (and Growing) Multiple Tailwinds Sleep business reached an inflection point following the Philips recall, which created a significant supply gap and drove patients to quality providers. We accelerated our growth through acquisitions of HMP (2023) and Lehan's (2025), building a national PAP therapy and resupply platform. GLP-1s and wearables continue to drive therapy demand. Addressable Market over 30 million in the United States 2025 Growth Metrics 3

VieMed Healthcare Inc. • Investor Presentation 13 ...and we’re still expanding our reach. Oxygen Therapy 8% of Revenue 2025 Growth Rate of 8% Tankless portable oxygen concentrators Device rentals with lifetime caps Earlier stages of COPD Growing referral channel from vent relationships Airway Clearance 7% of Revenue 2025 Growth Rate of 18% Nebulizers, cough assists, percussion vests Complements core respiratory offering Natural benefit to certain vent patients Expanding clinical evidence base Women's Health 6% of Revenue 2025 Growth Rate of 100% Breast pumps, insurance- covered, ship-to-home Nursing supplies and lactation accessories Compression garments and postpartum recovery Leverages existing payer relationships and ship-to-home infrastructure Healthcare Staffing 8% of Revenue 2025 Growth Rate of 12% Clinical resources to hospitals & agencies Supports continuum of care Deepens key referral relationships Provides operational flexibility (1) As a percentage of 4Q25 revenue (2) Maternal health reflects a partial year contribution following the acquisition of Lehan's Medical Equipment on July 1, 2025. 1 1 1 1 2

VieMed Healthcare Inc. • Investor Presentation Growth Strategy 14

VieMed Healthcare Inc. • Investor Presentation 15 Three engines driving our next chapter. O R G A N I C G R O W T H Geographic expansion into new target markets Densify existing markets Women’s health national rollout via existing payers Scale sleep through technology- enabled operations I N O R G A N I C G R O W T H Active M&A pipeline: complementary services Proven playbook: HMP, EAMC, Lehan Pristine balance sheet supports deal capacity Targets: platforms leveraging shared infrastructure O P E R A T I O N A L L E V E R A G E AI & technology driving efficiency across lines Declining capex intensity (capital-light mix shift) Favorable FCF margin mix (sleep/maternal growing faster) Shared infrastructure reduces incremental cost per service

VieMed Healthcare Inc. • Investor Presentation 16 Disciplined M&A has accelerated the platform… Complementary acquisitions leveraging our platform: successfully integrated and accretive June 2023 Complex respiratory synergies Accelerated sleep growth with mature resupply Geographic, product, and payor diversity April 2024 (JV) Referral source and patient base synergies Hospital JV partnership model Complementary to organic growth July 2025 Chicago market platform with brand equity Added women’s health to product offering Sleep rental, sales, and resupply synergies What We Look For: Complementary to core Leverages infrastructure Expands Offerings Expands Geography

VieMed Healthcare Inc. • Investor Presentation 17 … and the runway of opportunities is long. Our infrastructure, clinical expertise, and payor relationships position us to expand into additional complex home- based services as healthcare continues its shift toward home-based care delivery. S E C U L AR T A I L W I N D S CMS Push to Home Federal policy favoring home- based care delivery Aging Population Accelerating demand for complex home care Hospital Cost Pressure Systems seeking lower-cost care partners Stable Regulatory Environment Regulatory stability a strength for the industry The platform we’ve built has applications well beyond our current product set.

Regulatory Stability: Stable reimbursement environment and a new coverage standard that strengthens our position 18 VieMed Healthcare Inc. • Investor Presentation A Rate and Coverage Environment Working in Our Favor. Medicare Reimbursement + 2.0% - 2.8% CPI-driven rate increase took effect in January 2026. Competitive Bidding Program 2028 CMS has signaled a more limited program restart in 2028 Competitive Bidding Products Excluded CMS confirmed in December 2025 that VieMed's core product categories are excluded from the current round. Vent NCD Coverage Stable Long awaited NCD for ventilation a signal of CMS’ continued support for the complex therapy. New Coverage Determination: Near-Term Friction, Long-Term Tailwind. N E A R - T E R M National Coverage Determination (“NCD”) issued in June 2025 adds administrative and clinical complexity to ventilation therapy for both initial patient access and ongoing service. These new standards introduce an initial operational lift for suppliers. L O N G - T E R M Higher clinical standards strengthens VieMed's competitive position and our 24/7 RT model. Added complexity favors nationally-scaled providers like VieMed. Clear standards provide increased patients access for Commercial and Medicare Advantage payors. ✓ ✓ ✓

VieMed Healthcare Inc. • Investor Presentation Financial Performance 19

• Net revenues grew 21% Y-o-Y, reaching a new Company record • Adjusted EBITDA grew 20% Y-o-Y, reaching a new Company record • Diluted EPS grew 32% Y-o-Y, the 9th consecutive year of positive net income • Sleep therapy patients increased 62% Y-o-Y and sleep resupply patient count increased 49% Y-o-Y • Vent patients increased 4% Y-o-Y VieMed Healthcare Inc. • Investor Presentation $270M Net Revenue $61M Adjusted EBITDA $28M Free Cash Flow $14M Cash on Hand $0M Net Debt $46M Credit Facility Availability 9% Net Capex 9 Yrs Positive Net Income (1) See Appendix for non-GAAP reconciliations. (2) Expressed as a percentage of net revenue. 1 1 20 2025: Record results across the business… 2 1.98M Shares repurchased

VieMed Healthcare Inc. • Investor Presentation 21 …with sustained financial performance… FY 12/31/23 FY 12/31/24 FY 12/31/25 2026 Guidance Net Revenue $ 183.0M $ 224.3M $ 270.3M $ 315.0M Gross Margin % 61.6% 59.4% 57.5% Net Income Attr. to VMD $ 10.2M $ 11.3M $ 14.9M Adjusted EBITDA $ 43.1M $ 51.1M $ 61.4M $ 67.0M Adjusted EBITDA % 23.5% 22.8% 22.7% Free Cash Flow $ 21.7 $ 11.6M $ 28.1M As service mix diversifies, gross margins have moderately compressed, Adj EBITDA margins have held steady and free cash flow has expanded with the decline in capex intensity. 1 (1) Mid-point of 2026 annual guidance ranges. See slide 23 for additional information and commentary about our 2026 annual guidance.

VieMed Healthcare Inc. • Investor Presentation $- $50,000,000 $100,000,000 $150,000,000 $200,000,000 $250,000,000 $300,000,000 $350,000,000 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026E Revenue Adj. EBITDA (1) 2020, 2021 and 2022 includes $34.3 million, $8.6 million and $2.3 million of COVID-19 sales and services, respectively. (2) See reconciliation of Adjusted EBITDA in Appendix. (3) Mid-point of 2026 annual guidance ranges. See slide 23 for additional information and commentary about our 2026 annual guidance. 1 1 1 3 2 22 …and a long track record of consistent growth.

2026 Guidance & Commentary 23VieMed Healthcare Inc. • Investor Presentation Net Revenue $310M – $320M Full-Year 2026 Guidance Adjusted EBITDA $65M – $69M Full-Year 2026 Guidance Net CAPEX 10% – 11.5% of Net Revenue Revenue Cadence Q1 Flat to slightly down sequentially vs. Q4 2025; consistent with seasonal pattern Q2–Q4 Sequential revenue growth of 3% – 5% per quarter expected through year-end NEW Share Repurchase Authorization 5% of Shares Outstanding Our Board has authorized a new share repurchase program representing up to 5% of shares outstanding.

Capital Allocation Strategy 24VieMed Healthcare Inc. • Investor Presentation Our cash flow generation supports all three priorities simultaneously 1 INVEST IN ORGANIC GROWTH Fully funded by operating cash flow. Sleep tech scaling, women’s health national rollout, continued geographic expansion. 2 EXECUTE M&A P IPELINE Complementary acquisitions leveraging our platform. ~$0M net debt, $46M+ facility provides significant capacity. 3 RETURN CAPITAL TO SHAREHOLDERS 4th share repurchase program authorized. Three prior programs returned $26.3M (4.5M shares; $5.79 avg/share).

Why Own VMD 25VieMed Healthcare Inc. • Investor Presentation 1 Proven National Platform with Multiple High-Growth Opportunities Infrastructure serving 172,000+ patients across all 50 states, built over a decade of disciplined clinical execution. Ventilation anchor and complementary lines; all leveraging shared infrastructure and payor relationships. 2 Regulatory Stability 3 Industry Leading Financial Performance Building on nine straight years of positive net income, our maturing ventilation patient base combined with capital-light service lines are meaningfully expanding FCF. 4 Pristine Balance Sheet with M&A Optionality $0M net debt, an active acquisition pipeline, and a proven integration playbook for complementary businesses. 5 Disciplined Capital Allocation - Aligned from the Top Organic growth funded internally. Board has authorized a new share repurchase program. Insiders beneficially own more than 20% of shares outstanding; leadership's interests are squarely aligned with shareholders. NASDAQ: VMD Regulatory clarity on two fronts: ventilation coverage standards established, competitive bidding overhang removed.

VieMed Healthcare Inc. • Investor Presentation Appendix 26

Net CAPEX For the quarter ended 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 3/31/24 Purchase of property and equipment 8,737 7,636 8,129 15,483 11,829 11,002 8,934 6,006 Proceeds from sale of property and equipment (1,125) (1,671) (6,402) (6,953) (2,881) (6,033) (766) (641) Net CAPEX 7,612 5,965 1,727 8,530 8,948 4,969 8,168 5,365 Net Capex % of Net Revenue 10.0% 8.3% 2.7% 14.4% 14.7% 8.6% 14.9% 10.6% VieMed Healthcare Inc. • Investor Presentation (expressed in thousands of U.S. Dollars) 27

Liquidity Metrics Positioned for growth • The Company maintains a healthy balance sheet with effectively no net debt as of December 31, 2025, providing significant financial flexibility. • As of December 31, 2025, the Company had $46 million in unfunded commitments available under its existing credit facilities, supporting growth initiatives such as the acquisition of Lehan’s, which closed on July 1, 2025. For the period ended 12/31/25 12/31/24 12/31/23 Cash on hand $ 13,501 $ 17,540 $ 12,839 Working Capital $ 7,437 $ 15,554 $ 6,243 Long Term Debt $ 11,291 $ 3,589 $ 6,002 VieMed Healthcare Inc. • Investor Presentation (expressed in thousands of U.S. Dollars) 28

For the year ended 12/31/25 12/31/24 12/31/23 Net cash provided by operating activities $ 51,916 $ 39,089 $ 45,212 Less: Purchase of property and equipment (39,985) (37,771) (26,093) Proceeds from sale of property and equipment 16,151 10,321 2,588 Net CAPEX (23,834) (27,450) (23,505) Free Cash Flow $ 28,082 $ 11,639 $ 21,707 Net Capex % of Net Revenue 8.8% 12.2% 12.8% Net Capex % of Adjusted EBITDA 38.8% 53.7% 54.6% Free Cash Flow VieMed Healthcare Inc. • Investor Presentation Management believes free cash flow provides investors with useful insight into the company’s ability to generate cash, fund growth initiatives, and return capital to shareholders. Free cash flow is defined as net cash provided by operating activities, as reported under U.S. GAAP, less net capital expenditures (Net CAPEX). Net CAPEX is calculated as purchases of property and equipment minus proceeds from the sale of property and equipment in order to reflect both outflows and inflows associated with routine equipment turnover. Historically reported amounts of Free Cash Flow for the year ended December 31, 2023 has been recast to include the effect of proceeds from the sale of property and equipment. This adjustment aligns the calculation with the Company’s current presentation methodology and more accurately reflects net cash flows for capital expenditures by accounting for inflows on asset dispositions. (Expressed in thousands of U.S. Dollars) 29

Reconciliation of Adjusted EBITDA (1) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (2) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (3) Represents impairments of the fair value of investment and litigation-related assets. (Expressed in millions of U.S. Dollars) For the year ended: 2025 2024 2023 2022 2021 2020 2019 2018 2017 Net Income attributable to VieMed Healthcare, Inc. $ 14.9 $ 11.3 $ 10.2 $ 6.2 $ 9.1 $ 31.5 $ 8.5 $ 9.5 $ 7.7 Add back: Depreciation and amortization 28.7 25.3 21.9 15.6 11.3 9.6 6.4 3.8 2.5 Interest expense, net 1.2 0.8 0.4 0.2 0.3 0.5 0.3 0.2 0.3 Loss (gain) on derivative - - - - - - (0.4) 0.2 0.2 Stock-based compensation(1) 9.1 6.3 5.9 5.2 5.2 4.9 3.9 2.7 0.8 Transaction costs(2) 1.1 0.3 0.5 - - - - - - Impairment of assets(3) 2.3 - - - - - - - Income tax expense (benefit) 6.4 4.8 4.2 2.8 3.4 (5.2) 0.3 0.1 - Adjusted EBITDA $ 61.4 $ 51.1 $ 43.1 $ 30.0 $ 29.3 $ 41.3 $ 19.0 $ 16.5 $ 11.5 VieMed Healthcare Inc. • Investor Presentation Adjusted EBITDA is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. VieMed's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Management believes Adjusted EBITDA provides helpful information with respect to VieMed’s operating performance as viewed by management, including a view of VieMed’s business that is not dependent on the impact of VieMed’s capitalization structure and items that are not part of VieMed’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare VieMed’s operating performance on a consistent basis, (ii) to calculate incentive compensation for VieMed’s employees, (iii) for planning purposes, including the preparation of VieMed’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of VieMed’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating VieMed’s operating performance in the same manner as management. The table above is a reconciliation of net income attributable to VieMed Healthcare, Inc., the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated. In calculating Adjusted EBITDA, certain items(mostly non-cash) are excluded from net income including depreciation and amortization of capitalized assets, net interest expense, stock-based compensation, transaction costs, impairment of assets, and taxes. 30

(1) Refer to the previous slide for discussion of Adjusted EBITDA. (2) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (3) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (4) Represents impairments of the fair value of investment and litigation-related assets. For the quarter ended: 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 3/31/24 Net Income attributable to VieMed Healthcare, Inc. $ 5,639 $ 3,513 $ 3,157 $ 2,625 $ 4,316 $ 3,878 $ 1,468 $ 1,603 Add back: Depreciation & amortization 7,570 7,539 6,891 6,613 6,366 6,408 6,309 6,285 Interest expense, net 364 507 132 179 147 225 254 150 Stock-based compensation(2) 2,300 2,180 2,341 2,311 1,521 1,712 1,620 1,432 Transaction costs(3) 139 847 53 85 11 12 221 110 Impairment of assets(4) - - - - - 125 2,173 - Income tax expense 2,191 1,535 1,713 952 1,881 1,594 768 518 Adjusted EBITDA $ 18,203 $ 16,121 $ 14,287 $ 12,765 $ 14,242 $ 13,954 $ 12,813 $ 10,098 VieMed Healthcare Inc. • Investor Presentation (Expressed in thousands of U.S. Dollars) Reconciliation of Adjusted EBITDA1 31

VieMed Healthcare Inc. • Investor Presentation Financial and Operational Highlights (expressed in thousands of U.S. Dollars, except operational information). (1) Refer to slides 30-31 in this presentation for the definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure. (2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter. (3) PAP Therapy Patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter. (4) Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter. For the quarter ended: 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 3/31/24 Financial Information: Revenue $76,181 $71,914 $63,056 $59,129 $60,695 $58,004 $54,965 $50,593 Gross Profit $44,103 $41,345 $36,731 $33,279 $36,138 $34,371 $32,892 $29,802 Gross Profit % 58% 57% 58% 56% 60% 59% 60% 59% Net Income attributable to VieMed Healthcare, Inc. $5,639 $3,513 $3,157 $2,625 $4,316 $3,878 $1,468 $1,603 Cash and Cash Equivalents (As of) $13,501 $11,123 $20,016 $10,160 $17,540 $11,347 $8,807 $7,309 Total Assets (As of) $199,154 $202,360 $184,603 $178,079 $177,069 $169,526 $163,947 $154,875 Adjusted EBITDA(1) $18,203 $16,121 $14,287 $12,765 $14,242 $13,954 $12,813 $10,098 Operational Information: Vent Patients(2) 12,259 12,372 12,152 11,809 11,795 11,374 10,905 10,450 PAP Therapy Patients(3) 34,528 31,891 26,260 22,899 21,338 19,478 17,349 15,726 Sleep Resupply Patients(4) 36,561 33,518 25,246 22,941 24,478 22,143 20,185 18,904 32

FAQ

How did Viemed Healthcare (VMD) perform financially in 2025?

Viemed generated $270 million in net revenue and $61 million Adjusted EBITDA in 2025, with $28 million free cash flow. The company also recorded its ninth straight year of positive net income, underscoring a capital-light, home-based care model with expanding service lines.

What 2026 financial guidance did Viemed Healthcare (VMD) provide?

Viemed projects 2026 net revenue of $310–$320 million and Adjusted EBITDA of $65–$69 million. Net capex is expected to be 10%–11.5% of net revenue, reflecting continued investment in growth while maintaining strong cash generation and a capital-light equipment profile.

How diversified is Viemed Healthcare’s (VMD) revenue mix?

Viemed’s platform now spans ventilation, sleep, oxygen, airway clearance, women’s health and staffing. In Q4 2025, sleep represented 21% of net revenue, with ventilation, oxygen, airway clearance, maternal health and staffing contributing the balance, supporting multiple growth engines beyond its original ventilation focus.

What growth is Viemed Healthcare (VMD) seeing in its sleep business?

In 2025, Viemed’s sleep segment delivered 62% year-over-year PAP therapy patient growth and 49% year-over-year sleep resupply growth. Sleep accounted for 21% of Q4 2025 net revenue, reflecting acquisitions and increased demand from factors like device recalls and broader therapy adoption.

What is Viemed Healthcare’s (VMD) balance sheet and liquidity position?

As of December 31, 2025, Viemed reported effectively $0 million net debt, $13.5 million cash on hand, and $46 million of available commitments under credit facilities. Management highlights this balance sheet as supporting organic growth, acquisitions, and shareholder returns simultaneously.

Did Viemed Healthcare (VMD) authorize any share repurchases?

Yes. Viemed’s board authorized a new share repurchase program covering up to 5% of shares outstanding. The company notes this is its fourth such program, following three prior authorizations that collectively returned $26 million across 4 million shares at an average price of $5.79 per share.

How many patients does Viemed Healthcare (VMD) serve and in how many states?

Viemed reports serving over 172,000 patients across all 50 U.S. states through its home-based care platform. This footprint is built around complex respiratory services and has expanded into sleep, oxygen, airway clearance, women’s health products, and healthcare staffing relationships.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 45.0 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 20.2 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 11.7 KB